# CRISPR Technology * **Definition:** A revolutionary genome editing tool that allows for precise, targeted modifications to DNA in living organisms, utilizing a guide RNA to direct the Cas9 enzyme to specific genomic locations, enabling applications in gene therapy, disease modeling, and biotechnology. * **Taxonomy:** Healthcare Topics / CRISPR Technology ## News * Selected news on the topic of **CRISPR Technology**, for healthcare technology leaders * 2.5K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/29/2025 | [**North America Preventive Healthcare Technologies And Services Market Trends 2025**](https://www.linkedin.com/pulse/north-america-preventive-healthcare-technologies-tfraf/) | [[Linkedin]] | | 5/19/2025 | [**Trump's science adviser calls for return to 'gold-standard' research to kickstart stalled advances**](https://www.statnews.com/2025/05/19/trump-ostp-director-michael-kratsios-speaks-on-future-of-scientific-innovation/?utm_campaign=rss) | [[STAT]] | | 5/19/2025 | [**Trump's science adviser calls for return to 'gold standard' research to kickstart stalled advances**](https://www.statnews.com/2025/05/19/trump-ostp-director-michael-kratsios-speaks-on-future-of-scientific-innovation/) | [[STAT]] | | 5/9/2025 | [**Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina ...**](https://finance.yahoo.com/news/precision-medicine-market-analysis-report-131300143.html) | [[Yahoo Finance]] | | 5/1/2025 | [**Bipartisan support for federal research funding, and Dems sharpen arguments ... - STAT News**](https://www.statnews.com/2025/05/01/gop-senators-support-nih-biomedical-research-democrats-medicaid-work-requirements-rfk-jr-vaccines-dc-diagnosis-newsletter/) | [[STAT]] | | 3/17/2025 | [**The Future of Medicine: How 2025 Became the Year of Medical Breakthroughs - Medium**](https://medium.com/@jordycannon817/the-future-of-medicine-how-2025-became-the-year-of-medical-breakthroughs-7228c6f85a09) | [[Medium]] | | 3/7/2025 | [**The Future of Biotechnology: Medical, Food Technology, and Bioinformatics Innovations**](https://medium.com/@sourabh.more_60784/the-future-of-biotechnology-medical-food-technology-and-bioinformatics-innovations-37c067197fbb) | [[Medium]] | | 3/6/2025 | [**Global Genome Editing Market to Grow Rapidly at a CAGR ~13y 2032 - DelveInsight**](https://www.globenewswire.com/news-release/2025/03/06/3038530/0/en/Global-Genome-Editing-Market-to-Grow-Rapidly-at-a-CAGR-13-by-2032-DelveInsight.html) | [[Globe Newswire]] | | 2/26/2025 | [**CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032, Globally ...**](https://www.prnewswire.com/news-releases/crispr-market-is-expected-to-generate-a-revenue-of-usd-12-78-billion-by-2032--globally-at-15-85-cagr-verified-market-research-302386211.html) | [[PR Newswire]] | | 2/12/2025 | [**Genome Engineering Market To Reach USD 30.9 Billion by 2032, Growing at CAGR 16.7**](https://finance.yahoo.com/news/genome-engineering-market-reach-usd-122400738.html) | [[Yahoo Finance]] | | 1/19/2025 | [**NVIDIA Clara: Transforming Healthcare with AI-Powered Innovations - Medium**](https://medium.com/the-ai-entrepreneurs/nvidia-clara-transforming-healthcare-with-ai-powered-innovations-448617c90b52) | [[Medium]] | | 1/9/2025 | [**Global Biotechnology Market Outlook 2025: Driving Growth at 13.0AGR**](https://finance.yahoo.com/news/global-biotechnology-market-outlook-2025-153000473.html) | [[Yahoo Finance]] | | 12/7/2024 | [**Genotyping Market to Hit USD 59.31 Billion by 2032 with 14.27AGR - Report by S&S Insider**](https://finance.yahoo.com/news/genotyping-market-hit-usd-59-140000786.html) | [[Yahoo Finance]] | | 11/26/2024 | [**Genomic Testing Market Poised to Reach Valuation of US$ 32.95 Billion By 2032 - Astute Analytica**](https://finance.yahoo.com/news/genomic-testing-market-poised-reach-143000811.html) | [[Yahoo Finance]] | | 11/25/2024 | [**Stem Cell Therapy Market is expected to generate a revenue of USD 31.41 Billion by 2030 ...**](https://finance.yahoo.com/news/stem-cell-therapy-market-expected-151500703.html) | [[Yahoo Finance]] | | 11/22/2024 | [**Synthetic Biology Tools Market - A Global and Regional Analysis - LinkedIn**](https://www.linkedin.com/pulse/synthetic-biology-tools-market-global-regional-analysis-wdrbc) | [[Linkedin]] | | 11/20/2024 | [**7 Healthcare Trends That Will Transform Medicine In 2025 - Forbes**](https://www.forbes.com/sites/bernardmarr/2024/11/20/7-healthcare-trends-that-will-transform-medicine-in-2025/) | [[Forbes]] | | 10/4/2024 | [**Hyper-Personalized Medicine Market Research 2024: Size, Trends, Opportunities and Forecast 2020-2024 & 2025-2030 - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241004930872/en/Hyper-Personalized-Medicine-Market-Research-2024-Size-Trends-Opportunities-and-Forecast-2020-2024-2025-2030---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 8/29/2024 | [**Dr. Peter Rentrop Explores Revolutionary Medical Tech Breakthroughs That Will Change the Future**](https://marketsherald.com/dr-peter-rentrop-explores-revolutionary-medical-tech-breakthroughs-that-will-change-the-future/) | marketsherald.com | | 8/12/2024 | [**Gene Editing Market Strategic Insights: Growth Opportunities**](http://prsync.com/marketsandmarkets---hc/gene-editing-market-strategic-insights-growth-opportunities-4241204/) | [[PRSync]] | | 8/6/2024 | [**CRISPR Technology Research Report 2024 - Now Available**](https://finance.yahoo.com/news/crispr-technology-research-report-2024-130800305.html) | [[Yahoo Finance]] | | 7/3/2024 | [**The Power of Precision Medicine in Revolutionizing Healthcare**](https://www.healthcaretechoutlook.com/news/the-power-of-precision-medicine-in-revolutionizing-healthcare-nid-4193.html) | healthcaretechoutlook.com | | 7/2/2024 | [**Top 10 CRISPR Companies - Best DNA Editors**](https://media.market.us/top-10-crispr-companies/) | media.market.us | | 6/26/2024 | [**Life Sciences IT Market Analysis 2024-2033: Size, Share, Trends, And Competitive Landscape**](https://menafn.com/1108378831/Life-Sciences-IT-Market-Analysis-2024-2033-Size-Share-Trends-And-Competitive-Landscape) | menafn.com | | 2/21/2023 | [**Health tech**](https://www.fastcompany.com/section/health-tech) | [[Fast Company]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **CRISPR Therapeutics**: A biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. - **GenScript**: A global biotechnology company that offers gene synthesis and CRISPR services. - **GeneCopoeia**: A provider of gene editing tools and services, including CRISPR technology. - **ERS Genomics Limited**: Holds a comprehensive portfolio of CRISPR/Cas9 patents and licenses them for commercial applications. - **Caribou Biosciences**: A biotechnology company specializing in CRISPR technology for therapeutic applications. - **Pfizer**: Significant investments in biotechnology, including CRISPR technology for genetic disorders. - **Horizon Discovery Group**: A company focused on gene editing and gene modulation technologies, including CRISPR. - **Thermo Fisher Scientific**: A leading provider of scientific instruments and reagents, including CRISPR products. - **CorriXR**: A biotech company focused on enhancing cancer treatment using CRISPR-Cas technology to target drug resistance genes. - **Cellecta**: A biotechnology company specializing in CRISPR-based gene editing technologies. - **Abbott Laboratories**: A key player in the CRISPR market focusing on gene editing applications and personalized medicine. - **Emmanuelle Charpentier**: Microbiologist and co-inventor of CRISPR-Cas9 technology, pivotal in advancing genetic engineering. - **Jennifer Doudna**: Biochemist and co-inventor of CRISPR-Cas9 technology, recognized for her contributions to gene editing. - **Johnson & Johnson**: Investing heavily in R&D for new biotech products, including CRISPR applications. - **Intellia Therapeutics**: A biotechnology company focused on developing CRISPR-based therapies for genetic diseases. - **Medicines Discovery Catapult**: A UK-based organization that collaborates with ERS Genomics to enhance drug discovery using CRISPR. - **YolTech**: A clinical-stage company focused on developing CRISPR-based therapies with a pipeline of 10 genetic medicines targeting various diseases. - **Merck & Co., Inc.**: Another significant player in the CRISPR market, emphasizing strategic collaborations to enhance capabilities in oncology treatments. ### Partnerships and Collaborations - **CRISPR Therapeutics**: Formed strategic partnerships to enhance its gene editing efforts and expand its product portfolio. - **CRISPR Therapeutics and Bayer**: Strategic partnership aimed at enhancing research and development efforts in gene-based medicines. - **Integrated DNA Technologies and Innovative Genomics Institute**: Collaborating to create CRISPR treatments for genetic disorders. - **ERS Genomics and Medicines Discovery Catapult**: Entered a non-exclusive commercial-use CRISPR license agreement to enhance drug discovery capabilities. - **Mayo Clinic and multiple institutions**: Conducted a study utilizing CRISPR-Cas9 technology to analyze BRCA2 variants, improving genetic testing accuracy. - **ERS Genomics and Université de Montréal**: Announced a non-exclusive CRISPR/Cas9 license agreement to facilitate genome-wide CRISPR screening. - **YolTech and KACTUS**: Partnered to advance the commercialization of YolCas12TM, a proprietary DNA editor, in Greater China. - **KFSHRC and Saudi Patient Safety Center**: Signed a Memorandum of Understanding to promote patient safety through AI and CRISPR technology. - **BrightPath Bio and Cellistic**: Entered into a manufacturing agreement to advance allogeneic CAR-T cell therapy using iPSC-derived NKT cells. - **Cellino Biotech and various organizations**: Aims to establish strategic partnerships in personalized regenerative medicines. - **Lineage Cell Therapeutics and Eterna Therapeutics**: Collaborating to develop beta-2 microglobulin-deficient iPSC lines for treating central nervous system disorders. - **Vertex Pharmaceuticals and CMS**: Vertex is working with reimbursement authorities to ensure sustainable access to CASGEVY in multiple countries. - **KFSHRC and Harvard**: Collaborates on initiatives to enhance healthcare delivery and research. - **KFSHRC and WHO**: Promotes global health equity through shared advancements and expertise, particularly in telemedicine. ### Innovations, Trends, and Initiatives - **CRISPR-Cas9 Technology**: A precise gene-editing tool that allows for targeted DNA modifications, revolutionizing biotechnology and medicine. - **CRISPR Technology Growth**: The CRISPR market is projected to grow at a CAGR of 15.85% from 2026 to 2032, driven by advancements in gene editing applications. - **Bridge RNA Technology**: A new gene editing technique that allows for more precise DNA modifications, addressing some limitations of CRISPR. - **AI Integration**: Artificial intelligence is being leveraged to enhance CRISPR gene editing precision and reduce off-target effects. - **Bioinformatics Integration**: The integration of CRISPR with bioinformatics is enhancing genetic analysis and precision medicine. - **Investment in CRISPR Research**: Institutions worldwide are investing in CRISPR research, leading to a growing demand for skilled professionals in biotechnology. - **Market Growth**: The global CRISPR technology market is projected to grow from USD 4.2 billion in 2024 to USD 28.4 billion by 2034, with a CAGR of 9.5%. - **Hyper-Personalized Medicine**: Utilizing CRISPR and genomic data to tailor treatments to individual patients based on their genetic makeup. - **Gene Therapy Advancements**: CRISPR-based therapies gaining traction with regulatory approvals for conditions like sickle cell disease. - **FDA Approvals**: The FDA approved the first CRISPR gene-editing therapy for sickle cell disease, marking a significant milestone in gene therapy. - **AI Integration in Genomics**: Enhancing precision in identifying genetic mutations and accelerating personalized medicine. - **Induced Pluripotent Stem Cells (iPSCs)**: Highlighted as a significant innovation allowing development of any cell type for research and treatment without ethical concerns. - **Synthetic Biology Tools Market**: Projected to grow significantly, driven by advancements in gene editing and biotechnology. - **Next-Generation Sequencing**: Technologies are revolutionizing genomics, making DNA sequencing faster and more affordable. - **Personalized Medicine**: The shift towards personalized medicine is increasing demand for genome engineering, enabling targeted treatments for genetic disorders. - **AI Integration in Biotech**: Companies are leveraging AI to enhance drug discovery and genomic analysis, with platforms like NVIDIA Clara improving efficiency in healthcare. - **CAR T-cell Production Localization**: KFSHRC has localized CAR T-cell production, reducing treatment costs by 80% and improving access to therapies. ### Challenges and Concerns - **Ethical and Safety Concerns**: CRISPR technology raises ethical questions and safety concerns, prompting ongoing research to enhance its precision and safety for future applications. - **Ethical Concerns**: CRISPR technology raises ethical issues regarding human genome editing, influencing regulatory frameworks. - **Safety Issues**: CRISPR can inadvertently introduce new genetic defects, raising concerns about its clinical application. - **High Costs and Technical Complexity**: The high costs associated with CRISPR technology and the technical complexity pose barriers to widespread adoption. - **Regulatory Standards**: The establishment of regulatory standards for CRISPR applications is crucial to address safety and ethical concerns. - **Regulatory Challenges**: Biotech companies face evolving regulations that can delay the approval of CRISPR-based therapies. - **Accessibility Issues**: Despite advancements, there are challenges in ensuring equitable access to CRISPR therapies, particularly in community settings. - **High Treatment Costs**: Innovative CRISPR treatments, such as those for sickle cell disease, come with exorbitant costs, limiting patient access. - **Ethical Oversight**: KFSHRC emphasizes strict ethical oversight in CRISPR applications to protect patient rights and prevent bias. - **Ethical and Regulatory Challenges**: Concerns surrounding human germline editing and strict regulations complicate the innovation landscape. - **Safety Risks**: Off-target effects and safety concerns related to gene editing technologies raise apprehensions among stakeholders. - **Data Privacy**: Precision medicine faces challenges related to high costs and the need for interdisciplinary collaboration among healthcare professionals. - **Investment Challenges**: The cell and gene therapy sector has faced investment challenges since its peak in 2020 and 2021, although signs of recovery are emerging. - **Public Trust in AI**: Surveys indicate a lack of trust in AI for medical advice, highlighting the need for confidence-building. ## Related Topics [[CRISPR]]